Cargando…

Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?

BACKGROUND: The Coronavirus (COVID-19), (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)) has been spreading worldwide since its first identification in China. It has been speculated that patients with comorbidities and elderly patients could be at high risk for the pandemic reasoned re...

Descripción completa

Detalles Bibliográficos
Autores principales: Gemcioglu, Emin, Davutoglu, Mehmet, Ozdemir, Ese Ece, Erden, Abdulsamet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228888/
https://www.ncbi.nlm.nih.gov/pubmed/32480326
http://dx.doi.org/10.1016/j.msard.2020.102196
_version_ 1783534651793473536
author Gemcioglu, Emin
Davutoglu, Mehmet
Ozdemir, Ese Ece
Erden, Abdulsamet
author_facet Gemcioglu, Emin
Davutoglu, Mehmet
Ozdemir, Ese Ece
Erden, Abdulsamet
author_sort Gemcioglu, Emin
collection PubMed
description BACKGROUND: The Coronavirus (COVID-19), (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)) has been spreading worldwide since its first identification in China. It has been speculated that patients with comorbidities and elderly patients could be at high risk for the pandemic reasoned respiratory insufficiency and death. At first, it was thought that the patients who use immunmodulator therapy could be even at higher risks of disease complications. However, it has been also speculated about that using immunmodulators could be an advantage for the clinical prognosis. Therefore, several immunmodulators are currently being tested as potential treatment for COVID-19. METHODS: In this paper we report on a patient that has been treated with type 1 interferon for multiple sclerosis who developed COVID-19. RESULTS: Despite using immunmodulator, the symptoms of the patient at hospitalization were mild and he did not show elevated D-dimer, and there was no lymphopenia. He was discharged to home-quarantine with no symptoms. DISCUSSION: This report supports the idea of using type 1 interferon in the treatment could be effective in COVID-19 affected patients.
format Online
Article
Text
id pubmed-7228888
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-72288882020-05-18 Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19? Gemcioglu, Emin Davutoglu, Mehmet Ozdemir, Ese Ece Erden, Abdulsamet Mult Scler Relat Disord Case Report BACKGROUND: The Coronavirus (COVID-19), (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)) has been spreading worldwide since its first identification in China. It has been speculated that patients with comorbidities and elderly patients could be at high risk for the pandemic reasoned respiratory insufficiency and death. At first, it was thought that the patients who use immunmodulator therapy could be even at higher risks of disease complications. However, it has been also speculated about that using immunmodulators could be an advantage for the clinical prognosis. Therefore, several immunmodulators are currently being tested as potential treatment for COVID-19. METHODS: In this paper we report on a patient that has been treated with type 1 interferon for multiple sclerosis who developed COVID-19. RESULTS: Despite using immunmodulator, the symptoms of the patient at hospitalization were mild and he did not show elevated D-dimer, and there was no lymphopenia. He was discharged to home-quarantine with no symptoms. DISCUSSION: This report supports the idea of using type 1 interferon in the treatment could be effective in COVID-19 affected patients. Elsevier B.V. 2020-07 2020-05-16 /pmc/articles/PMC7228888/ /pubmed/32480326 http://dx.doi.org/10.1016/j.msard.2020.102196 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Case Report
Gemcioglu, Emin
Davutoglu, Mehmet
Ozdemir, Ese Ece
Erden, Abdulsamet
Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?
title Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?
title_full Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?
title_fullStr Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?
title_full_unstemmed Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?
title_short Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?
title_sort are type 1 interferons treatment in multiple sclerosis as a potential therapy against covid-19?
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228888/
https://www.ncbi.nlm.nih.gov/pubmed/32480326
http://dx.doi.org/10.1016/j.msard.2020.102196
work_keys_str_mv AT gemciogluemin aretype1interferonstreatmentinmultiplesclerosisasapotentialtherapyagainstcovid19
AT davutoglumehmet aretype1interferonstreatmentinmultiplesclerosisasapotentialtherapyagainstcovid19
AT ozdemireseece aretype1interferonstreatmentinmultiplesclerosisasapotentialtherapyagainstcovid19
AT erdenabdulsamet aretype1interferonstreatmentinmultiplesclerosisasapotentialtherapyagainstcovid19